Key result
The Micra-AV leadless pacemaker provides a promising alternative for atrioventricular synchronous pacing in patients with high-degree AV block, particularly those with high infective risk or limited venous access.
Why the study?
Second-generation leadless pacemakers expanded pacing modes to AV synchronous pacing, but recent reports highlighted concerns regarding these devices.
The Micra-AV leadless pacemaker offers a promising alternative for atrioventricular synchronous pacing in patients with high infection risk or limited venous access, though careful patient selection and device optimization are required.
Supports individualized leadless pacing in select high-risk patients; leaves open need for randomized trials before broader adoption.
Leadless pacemakers (LLPMs) have become a major breakthrough in the management of bradyarrhythmia as an attractive alternative to the standard transvenous pacemakers (TV-PMs). Recently, the introduction of a second-generation LLPMs (Micra AV-MC1AVR1) has expanded pacing modes to obtain atrioventricular (AV) synchronous pacing, providing an interesting alternative in the actual scenario of leadless pacing. Nevertheless, actual reports have highlighted some concerns regarding those devices. In this review, we sought to provide an overview of this technology based on its approval studies and major reports.
No takes yet. Share an insight, caveat, or question.
Mitacchione et al. (2021) conducted a review in Bradyarrhythmia and atrioventricular block. Micra AV-MC1AVR1 leadless pacemaker was evaluated. The Micra-AV leadless pacemaker provides a promising alternative for atrioventricular synchronous pacing in patients with high-degree AV block, particularly those with high infective risk or limited venous access.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: